Exploring Undervalued Small Caps With Insider Actions In Hong Kong June 2024

In This Article:

As of June 2024, the Hong Kong market is showing resilience with the Hang Seng Index posting a modest gain amidst mixed economic signals from mainland China. This context of fluctuating industrial outputs and retail sales growth provides a nuanced backdrop for investors looking at potential opportunities in undervalued small-cap stocks. In such an environment, identifying small-cap stocks that are potentially undervalued requires a keen understanding of market dynamics and insider actions, which can often provide critical insights into a company's future prospects.

Top 10 Undervalued Small Caps With Insider Buying In Hong Kong

Name

PE

PS

Discount to Fair Value

Value Rating

Wasion Holdings

11.5x

0.8x

29.09%

★★★★★☆

Xtep International Holdings

10.9x

0.8x

42.02%

★★★★★☆

Far East Consortium International

NA

0.3x

38.38%

★★★★★☆

Sany Heavy Equipment International Holdings

8.0x

0.7x

-22.26%

★★★★☆☆

Nissin Foods

14.9x

1.3x

36.60%

★★★★☆☆

China Leon Inspection Holding

10.2x

0.7x

24.74%

★★★★☆☆

China Lesso Group Holdings

4.1x

0.3x

7.53%

★★★★☆☆

Transport International Holdings

11.0x

0.6x

45.45%

★★★★☆☆

Giordano International

8.7x

0.8x

35.50%

★★★☆☆☆

China Overseas Grand Oceans Group

3.1x

0.1x

-11.60%

★★★☆☆☆

Click here to see the full list of 20 stocks from our Undervalued Small Caps With Insider Buying screener.

Here's a peek at a few of the choices from the screener.

Abbisko Cayman

Simply Wall St Value Rating: ★★★★☆☆

Overview: Abbisko Cayman is a company focused on the development of innovative medicines, with a market capitalization of CN¥19.06 million.

Operations: The company consistently reported a gross profit margin of 100% across multiple periods, with its latest revenue recorded at CN¥19.06 million. Significant operating expenses, including R&D which recently amounted to CN¥433.74 million, have led to a net income margin improvement from -25.32% to -22.64%.

PE: -4.5x

Abbisko Cayman, a Hong Kong-based entity, recently initiated a share repurchase on June 18, 2024, signaling insider confidence by authorizing up to 10% of its issued capital for buyback. Despite lacking significant revenue (CN¥19M) and profitability forecasts for the next three years, the company is anticipated to see a substantial revenue growth of about 39% annually. This financial maneuver coupled with strategic executive changes and regulatory advancements in its pharmaceutical developments underscore a proactive approach in enhancing shareholder value amidst its current undervaluation in the market.